Cargando…
Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia
BACKGROUND: Chemotherapy used to treat malignancy can lead to loss of skeletal muscle mass and reduced force production, and can reduce bone volume in mice. We have shown that bone-muscle crosstalk is a key nexus in skeletal muscle function and bone homeostasis in osteolytic breast cancer bone metas...
Autores principales: | Hain, Brian A., Xu, Haifang, Wilcox, Jenna R., Mutua, Daniel, Waning, David L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481302/ https://www.ncbi.nlm.nih.gov/pubmed/31032492 |
Ejemplares similares
-
Loss of REDD1 prevents chemotherapy‐induced muscle atrophy and weakness in mice
por: Hain, Brian A., et al.
Publicado: (2021) -
Differential Bone Loss in Mouse Models of Colon Cancer Cachexia
por: Bonetto, Andrea, et al.
Publicado: (2017) -
Role of TGF-β in breast cancer bone metastases
por: Chiechi, Antonella, et al.
Publicado: (2013) -
Osteolytic Breast Cancer Causes Skeletal Muscle Weakness in an Immunocompetent Syngeneic Mouse Model
por: Regan, Jenna N., et al.
Publicado: (2017) -
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo
por: Wright, Laura E., et al.
Publicado: (2016)